AKBA

Q: What is the price of Akebia Therapeutics (AKBA) today?

The current price of Akebia Therapeutics (AKBA) is $ 0.94, representing a -71.19% gain over the past year. The stock began the year trading around $ 1.61 and is currently priced at $ 0.94. You can follow the real-time price chart, review historical performance, and track broader market trends directly on the platform.

Q: When does Akebia Therapeutics (AKBA) pay dividends?

Akebia Therapeutics (AKBA) did not pay dividends over the past year.

Akebia Therapeutics Inc.

Price

$ 0.94

return (12m)

-71.19%

p/e

-13.28

p/bv

9.95

DIVIDEND YIELD

0.00%

AKBA price

Akebia Therapeutics

If you had invested

exposure

years ago

7 days

30 days

6 months

YTD

1 year

5 years

10 years

15 years

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment AKBA

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

-33.11%

3 months

-25.09%

1 year

-71.19%

2 years

-16.39%

5 years

-71.88%

10 years

0.00%

Fundamentals AKBA

review the fundamentals of Akebia Therapeutics shares

P/E

-13.28

Sector: -3.99 Industry: -3.99

P/S (PSR)

1.17

Sector: -4.17 Industry: -4.17

P/BV

9.95

Sector: 2.00 Industry: 2.00

DIVIDEND YIELD (DY)

0.00%

Sector: - Industry: -

ROA

-5.65%

Sector: -65.15% Industry: -65.15%

ROE

-74.87%

Sector: -65.39% Industry: -65.39%

ROIC

-7.60%

Sector: -2,913.92% Industry: -2,913.92%

NET MARGIN

-8.82%

Sector: -40.35% Industry: -40.35%

GROSS MARGIN

81.01%

Sector: 36.51% Industry: 36.51%

OPERATING MARGIN

2.28%

Sector: -39.30% Industry: -39.30%

EV/EBITDA

75.23

Sector: -4.10 Industry: -4.10

EV/EBIT

116.88

Sector: -4.18 Industry: -4.18

PRICE-TO-ASSETS

0.75

Sector: 1.47 Industry: 1.47

BVPS

0.10

Sector: 1.88 Industry: 1.88

EPS

-0.08

Sector: -2.14 Industry: -2.14

EQUITY-TO-ASSETS RATIO

0.08

Sector: 0.42 Industry: 0.42

LIABILITIES / ASSETS

0.92

Sector: 0.40 Industry: 0.40

CAGR REVENUE 5 YEARS

1.89%

Sector: - Industry: -

CAGR PROFIT 5 YEARS

-40.80%

Sector: - Industry: -

Fundamentals AKBA

DRAG THE FRAME TO SEE MORE DATA

Stock Comparison Tool

DRAG THE FRAME TO SEE MORE DATA

	p/e	p/bv	ROE	dy	market cap	net margin
JNJ	25.65	6.65	25.92%	2.32%	$ 539.72 B	21.83%
PFE	19.57	1.62	8.29%	6.68%	$ 146.58 B	11.83%
ABBV	106.01	-58.28	-54.98%	3.10%	$ 385.36 B	5.79%
NVO	10.68	6.45	60.40%	4.09%	$ 202.51 B	37.15%
MRK	32.85	6.39	19.45%	2.80%	$ 293.48 B	13.59%
AZN	27.68	6.07	21.93%	1.72%	$ 287.60 B	17.19%
GILD	18.12	7.13	39.33%	2.37%	$ 166.96 B	30.99%
BMY	16.02	5.80	36.19%	4.37%	$ 116.53 B	15.01%
ZTS	12.27	10.03	81.75%	2.64%	$ 32.42 B	27.79%
REGN	14.45	2.03	14.08%	0.58%	$ 63.94 B	29.65%
HALO	22.51	35.75	158.82%	0.00%	$ 7.85 B	23.13%
AMGN	23.32	19.79	84.87%	2.87%	$ 181.87 B	20.96%
MCK	19.02	-108.61	-570.98%	0.43%	$ 90.58 B	1.18%
HRMY	12.58	2.01	16.00%	0.00%	$ 1.83 B	16.20%
VRTX	26.20	5.87	22.41%	0.00%	$ 113.68 B	35.51%
CAH	29.74	-17.31	-58.20%	1.04%	$ 46.25 B	0.62%
ADMA	11.39	4.82	42.37%	0.00%	$ 1.88 B	32.43%

Stock vs Indice Comparison Tool

If you had invested

years ago

2 years

5 years

10 years

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

AKBA Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Akebia Therapeutics

Akebia Therapeutics Inc.

Average Investor10 user rating

4.0 (1 people)

United States

19 years

Founded: 2007

2014

Time since IPO - 12 years

380

Employees

Akebia Therapeutics Inc. (United States) is listed on the Nasdaq and has a market capitalization of $272.34 Millions, with shareholders equity totaling $27.38 Millions.

The company employs approximately 380 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Akebia Therapeutics Inc. reported $232.40 Millions in revenue, generating net income of $-20.50 Millions.

Key financial metrics include a P/E ratio of -13.28, a price-to-book (P/B) ratio of 9.95, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker AKBA.

Market cap

$ 272.34 Millions

Net worth

$ 27.38 Millions

$ 27,380,000.00

Assets

$ 362.52 Millions

$ 362,520,000.00

Total Shares Outstanding

267.00 Millions

267,000,000

Average Daily Trading Volume

$ 3.68 Millions

$ 3,675,338.18

Sector

Health Care

Industry

Biotechnology

AKBA

AKBA revenue and profits

Financial Results AKBA

DRAG THE FRAME TO SEE MORE DATA

AKBA cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more stocks

BFRA - Biofrontera

$ - -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$ 736.78 3,58% (12M)

P/E

19.02

0.43%

ROE

-570.98%

P/BV

-108.61

CAH - Cardinal Health

$ 194.88 27,10% (12M)

P/E

29.74

1.04%

ROE

-58.20%

P/BV

-17.31

JNJ - Johnson & Johnson

$ 222.89 49,23% (12M)

P/E

25.65

2.32%

ROE

25.92%

P/BV

6.65

MRK - Merck & Co.

$ 115.65 56,46% (12M)

P/E

32.85

2.80%

ROE

19.45%

P/BV

6.39

AZN - AstraZeneca

$ 177.45 23,67% (12M)

P/E

27.68

1.72%

ROE

21.93%

P/BV

6.07

ABBV - AbbVie

$ 215.40 18,69% (12M)

P/E

106.01

3.10%

ROE

-54.98%

P/BV

-58.28

NVO - Novo Nordisk

$ 42.92 --36,54% (12M)

P/E

10.68

4.09%

ROE

60.40%

P/BV

6.45

BFRA - Biofrontera

$ - -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$ 736.78 3,58% (12 M)

P/L

19.02

0.43%

ROE

-570.98%

P/VP

-108.61

CAH - Cardinal Health

$ 194.88 27,10% (12 M)

P/L

29.74

1.04%

ROE

-58.20%

P/VP

-17.31

JNJ - Johnson & Johnson

$ 222.89 49,23% (12 M)

P/L

25.65

2.32%

ROE

25.92%

P/VP

6.65

MRK - Merck & Co.

$ 115.65 56,46% (12 M)

P/L

32.85

2.80%

ROE

19.45%

P/VP

6.39

AZN - AstraZeneca

$ 177.45 23,67% (12 M)

P/L

27.68

1.72%

ROE

21.93%

P/VP

6.07

ABBV - AbbVie

$ 215.40 18,69% (12 M)

P/L

106.01

3.10%

ROE

-54.98%

P/VP

-58.28

NVO - Novo Nordisk

$ 42.92 --36,54% (12 M)

P/L

10.68

4.09%

ROE

60.40%

P/VP

6.45

Frequently Asked Questions

What is the price of Akebia Therapeutics (AKBA) today?

The current price of Akebia Therapeutics (AKBA) is $ 0.94, representing a -71.19% gain over the past year. The stock began the year trading around $ 1.61 and is currently priced at $ 0.94. You can follow the real-time price chart, review historical performance, and track broader market trends directly on the platform.

When does Akebia Therapeutics (AKBA) pay dividends?

Akebia Therapeutics (AKBA) did not pay dividends over the past year.

Is Akebia Therapeutics (AKBA) a good investment?

Akebia Therapeutics (AKBA) is currently trading at $ 0.94 with a P/E ratio of -13.28. This represents a -2,074% premium compared to its historical average P/E. Over the past year, the stock has gained -71.19 and paid $ 0.00 in dividends, resulting in a dividend yield of 0.00%. The total shareholder return over the same period was -71.19%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Akebia Therapeutics (AKBA) stock?

You can buy Akebia Therapeutics (AKBA) shares through any brokerage account that provides access to U.S. stock exchanges. After opening and funding your account, simply search for the ticker symbol AKBA and place a buy order. Before investing, consider factors such as your financial goals, risk tolerance, and overall portfolio allocation.

How much would 100 shares of Akebia Therapeutics (AKBA) yield today?

Over the past month, Akebia Therapeutics (AKBA) has returned -33.11% — -71.19% over the past year, and -71.88% over the past five years, including price appreciation and dividends.

In the last 12 months, the company paid a total of 0.00 per share in dividends, resulting in a dividend yield of 0.00%.

If you were to purchase 100 shares of Akebia Therapeutics (AKBA) today at the current price of $ 0.94 your total investment would be $ 93.64.

Based on historical performance, the investment would have grown to approximately:

$ 26.98 after 1 year
$ 26.33 after 5 years
$ 93.64 after 10 years

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

AKBA

Akebia Therapeutics Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment AKBA

review the fundamentals of Akebia Therapeutics shares

P/E

P/S (PSR)

P/BV

DIVIDEND YIELD (DY)

ROA

ROE

ROIC

NET MARGIN

GROSS MARGIN

OPERATING MARGIN

EV/EBITDA

EV/EBIT

PRICE-TO-ASSETS

BVPS

EPS

EQUITY-TO-ASSETS RATIO

LIABILITIES / ASSETS

CAGR REVENUE 5 YEARS

CAGR PROFIT 5 YEARS

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Akebia Therapeutics

Akebia Therapeutics Inc.

United States

19 years

2014

380

PROFIT X PRICE AKBA

Financial Results AKBA

AKBA cash flow

Asset, Revenue and Profit Growth - AKBA

AKBA balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

MRK - Merck & Co.

AZN - AstraZeneca

ABBV - AbbVie

NVO - Novo Nordisk

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

MRK - Merck & Co.

AZN - AstraZeneca

ABBV - AbbVie

NVO - Novo Nordisk

Frequently Asked Questions